

## AIDS 2020 Track B abstract submission categories

| Track B – Clinical research  |  |
|--|--|
| <b>Course of HIV disease</b>   |  |
| B1   | Acute and early infection  |
| B2   | Impact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression                |
| B3   | Morbidity, mortality and life expectancy in clinical research  |
| <b>Diagnostic and monitoring tools</b>                                   |  |
| B4   | HIV testing and retesting (e.g., point-of-care diagnostics)  |
| B5   | Viral load and CD4 monitoring  |
| B6   | Adherence testing  |
| B7   | Resistance to ART  |
| B8   | Diagnostics of co-infections and co-morbidities  |
| B9   | Biomarkers for the prediction of morbidity and mortality   |
| <b>Co-infections (including opportunistic infections)</b>                |  |
| B10  | Tuberculosis: Prevention, diagnosis, treatment   |
| B11  | Opportunistic infections (excluding TB): Bacterial, non-TB mycobacterial, viral and parasitic infections |
| B12  | Viral hepatitis C  |
| B13  | Other viral hepatitis (e.g., A, B, D, E)   |
| B14  | STIs (including HPV)   |
| <b>Co-morbidities and complications (including those related to ART)</b> |  |
| B15  | Neurologic disorders   |
| B16  | Depression and other psychiatric manifestations  |
| B17  | Malignancies (AIDS and non-AIDS)   |
| B18  | Cardiovascular disease   |
| B19  | Bone disease   |
| B20  | Renal disease  |
| B21  | Metabolic, lipid and endocrine complications (including lipodystrophy)                                   |
| B22  | Weight gain  |
| B23  | Hepatic complications (e.g., NASH)   |
| B24  | Mental health and HIV  |
| B25  | Ageing with HIV (including polypharmacy and frailty)   |
| B26  | Immune reconstitution disorders/immune reconstitution inflammatory syndrome (IRIS)                       |
| B27  | Other ART complications and adverse reactions  |
| B28  | Other non-communicable diseases  |
| B29  | Co-morbidities and ART complications in key populations  |
| <b>Antiretroviral therapies in adults</b>                                |  |
| B30  | ART in acute, first- and second-line therapies   |

|   |   |
|---|---|
| B31   | ART in highly treatment-experienced persons   |
| B32   | Regimen simplification and switch studies   |
| B33   | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring  |
| B34   | Drug interactions   |
| B35   | Antiretroviral drug resistance  |
| B36   | Long-acting agents and other drug delivery systems (e.g., injectables, implants, microneedle patches)                       |
| B37   | Adherence   |
| B38   | Ethical issues in clinical trials and treatment strategies  |
| <b>Other strategies and therapies</b>   |   |
| B39   | Therapeutic vaccine trials  |
| B40   | Cure interventions  |
| B41   | Complementary and traditional medicines   |
| B42   | Nutrition   |
| <b>Clinical issues specific to gender</b>                                     |   |
| B43   | Sex-specific issues of ART efficacy, adverse reactions and complications  |
| B44   | Pregnancy (clinical management issues and pharmacokinetics)   |
| B45   | Contraception   |
| B46   | Menopause   |
| <b>Clinical issues specific to paediatric and adolescent HIV</b>              |   |
| B47   | Diagnosis of HIV disease in paediatric and adolescent populations   |
| B48   | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
| B49   | Drug formulations for infants and children  |
| B50   | Clinical trials in paediatric and adolescent populations  |
| B51   | ARV management strategies in paediatric and adolescent populations  |
| B52   | Cure strategies in paediatric and adolescent populations  |
| B53   | Adherence in paediatric and adolescent populations  |
| B54   | Opportunistic infections in paediatric and adolescent populations   |
| B55   | TB/HIV co-infection in paediatric and adolescent populations (including treatment and prevention)                           |
| B56   | HIV complications and co-morbidities in paediatric and adolescent populations   |
| B57   | HIV-associated co-infections and malignancies in paediatric and adolescent populations                                      |
| B58   | Behavioural health outcomes in paediatric and adolescent populations  |
| B59   | Mental health and neurocognition in paediatric and adolescent populations   |
| B60   | HIV-exposed uninfected children   |
| B61   | Transition of adolescents into adult care   |
| <b>Clinical issues specific to key populations and vulnerable populations</b> |   |
| B62   | Clinical issues in men who have sex with men  |
| B63   | Clinical issues in sex workers  |
| B64   | Clinical issues in transgender people   |
| B65   | Clinical issues in people who use drugs   |

|                 |   |
|-----------------|---|
| B66             | Clinical issues in other vulnerable populations, including unstable settings (migrants) and incarcerated settings |
| B67             | Ethical considerations related to clinical research with key populations and other vulnerable populations         |
| <b>COVID-19</b> |   |
| B68             | Use of HIV-related antiviral agents in COVID-19 prevention and treatment  |
| B69             | Clinical manifestations and features of COVID-19 and HIV co-infection   |